Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Development Attainment Motivation Career Growth Concept. Mans Hand Reaching For Red Ladder Leading To A Blue Sky

Roivant Sciences GMBH may be best known for a big late-stage failure in Alzheimer's disease with the publicly-traded firm Axovant Sciences Ltd., but its family of companies has ballooned to include 10 biopharma "vants" – including the newly revealed Immunovant – and two other vants focused on health care data and emerging markets. The company held its first annual pipeline day for investors July 9 in New York City to showcase progress across the portfolio and toward its goal of creating a drug development accelerator.

"Most of our resources are in pharma – drug assets where we believe the magnitude of the unmet medical need...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.